ClinicalTrials.gov
public full text
Public Domain
Sentinel Node After Neoadjuvancy In Node-Positive Breast Cancer
The status of the axillary lymph nodes is one of the main prognostic factors in breast cancer (BC). SLNB is currently the standard staging method for patients with clinically node-negative (cN0) breast cancer. In patients with a positive SLN and in those with affected lymph nodes at the beginning (cN+), LND is the standard of treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy#1363994
- Radiotherapy and Long-term Outcomes in Early Breast Cancer With SLNB Omission#1323642
- Construction and validation of a pretreatment DCE-MRI-based radiomics prediction model for axillary pathologic response after neoadjuvant therapy in node-positive breast cancer.#280912
- A Prospective Single-center Cohort Study "Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients"#1323787
- Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC#837584
Record · ID 1245995
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive